Neuromuscular Disease Modeling
Model neuromuscular disorders including Myasthenia Gravis, ALS, and genetic NMJ diseases using patient-derived iPSC systems, enabling analysis of NMJ damage and protective mechanisms.
Ready-to-use. Human-based. Purpose-built for reliable neuromuscular modeling.
NeuroMuscle™ is a fully human neuromuscular junction (NMJ)-on-a-chip platform that combines iPSC-derived motor neurons and 3D skeletal muscle within a microfluidic system to recreate functional neuromuscular signaling in vitro. Designed as a plug-and-play, plate-based system, NeuroMuscle™ operates like a standard multi-well culture plate—requiring no pumps, tubing, controllers, or specialized hardware—and integrates seamlessly into existing laboratory workflows.
Each disposable plate contains 20 independent, functional NMJs, enabling parallel testing across multiple conditions while supporting high-content imaging, functional assays, and automated analysis. The platform delivers quantitative, real-time readouts of neuromuscular communication and muscle contraction, providing insights that are difficult or impossible to obtain from traditional in vitro or animal models.
NeuroMuscle™ has been successfully transferred and established in external laboratories, including regulatory and industry environments, demonstrating robustness, reproducibility, and ease of implementation. The platform supports both in-house use and CRO-led study execution, with options for ready-to-use, pre-assembled NMJs.




Structural and Functional Immunofluorescence Characterization of NMJ tissues
NeuroMuscle™ supports a broad range of neuromuscular research, safety, and translational applications, enabling functional, human-relevant evaluation that bridges discovery, regulatory science, and human impact.
Model neuromuscular disorders including Myasthenia Gravis, ALS, and genetic NMJ diseases using patient-derived iPSC systems, enabling analysis of NMJ damage and protective mechanisms.
Evaluate small molecules, biologics, and antibodies through functional efficacy, mechanism-of-action, and longitudinal therapeutic response studies in fully human NMJ systems.
Detect and quantify neuromuscular toxicity, including botulinum neurotoxin activity, environmental neurotoxins, and pharmaceutical safety profiles using functional contractility-based assays.
Examples demonstrating the capabilities of the NeuroMuscle™ platform. Detailed datasets and study designs are available upon request.
NeuroMuscle™ has been used to model autoimmune-mediated neuromuscular junction (NMJ) dysfunction using human motor neurons and skeletal muscle. By exposing human NMJs to disease-relevant conditions, the platform captures functional loss of neuromuscular transmission and enables longitudinal assessment of therapeutic protection and recovery.
What this demonstrates